Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

Deciphera Pharmaceuticals logo

About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)

Advanced Chart

Key Stats

Today's Range
$25.59
$25.59
50-Day Range
$25.55
$25.59
52-Week Range
$9.90
$25.61
Volume
600 shs
Average Volume
1.29 million shs
Market Capitalization
$2.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Stock News Headlines

Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
See More Headlines

DCPH Stock Analysis - Frequently Asked Questions

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its quarterly earnings results on Tuesday, February, 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.04. The company's revenue for the quarter was up 32.9% on a year-over-year basis.
Read the conference call transcript
.

Deciphera Pharmaceuticals (DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
2/06/2024
Today
5/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
300
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$194.94 million
Net Margins
-108.86%
Pretax Margin
-108.62%

Debt

Sales & Book Value

Annual Sales
$174.91 million
Price / Cash Flow
N/A
Book Value
$4.38 per share
Price / Book
5.84

Miscellaneous

Free Float
82,438,000
Market Cap
$2.21 billion
Optionable
Optionable
Beta
0.19
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:DCPH) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners